SA
TSHA logo
Taysha Gene Therapies, Inc.(TSHA)
Closing price · checked 4:31 PM ETAbout this dataData status
$3.77▼-0.22 (-5.51%)
After Hours:$3.77+0.00 (+0.00%)· 4:31 PM ET

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 28.4 · elevated volatility

Overview →
Next report

Mar 18 2027in 119 days

EPS estimate

($0.11)

Revenue estimate

$2M

EPS beats

8 of last 12

Earnings SurpriseEPS, actual vs estimateLatest +22.2%

How far reported EPS beat (+) or missed (−) the analyst estimate that stood when each report landed.

2024: 9.1%2024: 10.0%2024: -12.5%2025: 12.5%2025: 0.0%2025: -28.6%2025: 0.0%2026: 27.3%2026: -20.0%2026: -14.8%2026: 22.2%9.1%-12.5%0.0%0.0%-20.0%22.2%
May 14 2024Nov 12 2026
ReportedEPS estEPS actualSurpriseRevenue estRevenue actualSurprise
Nov 12 2026($0.13)($0.10)+22.2%$755556——
Aug 11 2026($0.11)($0.13)-14.8%$680000——
May 6 2026($0.10)($0.12)-20.0%$755556——
Mar 19 2026($0.11)($0.08)+27.3%$2M$5M+144.5%
Nov 4 2025($0.09)($0.09)+0.0%$2M——
Aug 12 2025($0.07)($0.09)-28.6%$2M$2M+14.9%
May 15 2025($0.08)($0.08)+0.0%$1M$2M+112.3%
Feb 26 2025($0.08)($0.07)+12.5%$2M$2M-1.5%
Nov 13 2024($0.08)($0.09)-12.5%$2M$2M-12.9%
Aug 12 2024($0.10)($0.09)+10.0%$3M$1M-58.2%
May 14 2024($0.11)($0.10)+9.1%$3M$3M+33.2%
Mar 19 2024($0.09)$0.35+488.9%$3M$4M+36.0%

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+1089.77%
EPS—
FY2028
Rev+663.17%
EPS—
FY2029
Rev+252.00%
EPS—
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$2M$19M$149M$523M$1.04B
Low$863,817$10M$27M$276M$549M
High$3M$31M$304M$838M$1.67B
EBITDA Avg$-161M$-150M$-100M$186M$542M
Low$-161M$-177M$-158M$99M$272M
High$-130M$-108M$41M$298M$886M
EBIT Avg$-162M$-152M$-111M$144M$441M
Low$-162M$-179M$-169M$57M$172M
High$-131M$-110M$30M$255M$786M
Net Income Avg$-164M$-154M$-113M$112M$347M
Low$-164M$-180M$-171M$43M$134M
High$-132M$-112M$22M$200M$619M
EPS Avg$-0.44$-0.45$-0.20$0.35$1.09
Low$-0.51$-0.56$-0.53$0.14$0.42
High$-0.41$-0.35$0.07$0.63$1.94
Analysts (Rev / EPS)7 / 77 / 66 / 74 / 23 / 4
Quarterly
MetricQ4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg$2M$685,714$685,714$685,714$17M
Low$2M$685,714$685,714$685,714$17M
High$2M$685,714$685,714$685,714$17M
EBITDA Avg$-41M$-43M$-44M$-46M$-42M
Low$-44M$-43M$-44M$-46M$-42M
High$-37M$-43M$-44M$-46M$-42M
EBIT Avg$-41M$-43M$-45M$-47M$-43M
Low$-45M$-43M$-45M$-47M$-43M
High$-37M$-43M$-45M$-47M$-43M
Net Income Avg$-41M$-43M$-45M$-47M$-43M
Low$-45M$-43M$-45M$-47M$-43M
High$-37M$-43M$-45M$-47M$-43M
EPS Avg$-0.10$-0.11$-0.11$-0.12$-0.11
Low$-0.11$-0.11$-0.11$-0.12$-0.11
High$-0.09$-0.11$-0.11$-0.12$-0.11
Analysts (Rev / EPS)9 / 38 / 35 / 14 / 15 / 1

Q3 2026
Checking for summary...

Last reported Earnings history refreshes daily; a new report appears within about 2 daysAbout this data

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.